BELLEVUE, WA, May 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today announced that it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration for PX-866, a small molecule phosphatidylinositol-3-kinase (PI-3-kinase) inhibitor for the treatment of advanced cancers. Following FDA review, Oncothyreon plans to initiate a Phase 1 clinical trial of PX-866.
"PX-866 is a potent inhibitor of phosphatidylinositol-3-kinase that has demonstrated preclinical anti-tumor activity in models of human ovarian cancer, lung cancer and intracranial glioblastoma," said Lynn Kirkpatrick, Ph.D., Chief Scientific Officer of Oncothyreon. "We believe that PX-866, an irreversible inhibitor of the kinase, will have dose and schedule advantages that may position it well in the current field of PI-3-kinase inhibitors."
"This IND for PX-866 demonstrates the continued advancement of Oncothyreon's small molecule oncology pipeline," said Robert L. Kirkman, M.D., President and CEO of Oncothyreon. In addition to the planned trial of PX-866, Oncothyreon is currently conducting a Phase 2 trial of PX-12, a small molecule inhibitor of thioredoxin-1, in patients with advanced pancreatic cancer and a Phase 1 trial of PX-478, a small molecule inhibitor of HIF-1 alpha, in patients with advanced solid tumors or lymphomas.
PX-866 is an inhibitor of the PI-3-kinase/PTEN/AKT pathway, an
important survival signaling pathway that is activated in many types of
human cancer. Aberrant activation and regulation of PI-3 kinase is
implicated in a large proportion of human cancers including breast, glioma,
colon, ovarian, prostate and melanoma, where it leads to increased
proliferation and inhibition of apoptosis (programmed cell death). PX-866
has been shown to induce prolonged inhibition of tumor PI-3 kinase
signaling following both oral and intravenous administration. The compound
has been shown to have goo
|SOURCE Oncothyreon Inc.|
Copyright©2008 PR Newswire.
All rights reserved